Page 2 - Cipla

Cipla rallies 4%, hits 52-week high; Choice Broking sees more upside

Cipla stock outlook: A decisive breakout above ₹1,580 could trigger further upward momentum, paving the way towards the ₹1,770-₹1,850 target range in the medium term, said Choice Broking.

Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Dr Reddy's, Sun: Pharma stocks can crash up to 30% on Trump's 100% tariff

Indian pharma shares - Dr.Reddy's, Cipla, Sun, Lupin and Aurobindo Pharma stare at up to 30 downside risk hint technical charts as US President Donald Trump announces 100% tariff on pharma imports.

Cipla launches Huena, India's first non-antibiotic drug to fight UTI

Drug firm Cipla on Friday said it has introduced a non-antibiotic treatment for patients suffering from recurrent urinary tract infections. The company has launched Methenamine Hippurate under the brand name HUENA. This marks a significant step forward for the company in its fight against anti-microbial resistance as it becomes the first to introduce such treatment in India, the Mumbai-based drugmaker said in a statement. Urinary tract infections (UTIs) are the second most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. Women are more susceptible to UTIs, which account for 15 per cent of overall antibiotic prescriptions. Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies show it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance. "We believe this ...

Looking for short-term F&O trade? Check this 'Bull Spread' on Cipla

Short term trend is positive as it is placed above its 5, 11 and 20 day EMA Stock price has broken out on the weekly chart with higher volumes

Next US fix could stanch Cipla's Revlimid bleed amid pricing pressure

Generics pipeline starts to pulse as Advair, Symbicort, and Abraxane prepare to hit the vein

Cipla Q1 net profit up 10%, driven by consumer health and generics

Cipla reports a 10% increase in Q1FY26 net profit, fueled by strong performance in the generics and consumer health segments

Cipla Q1 FY26 result: Net profit jumps 10% at ₹1,298 cr, income rises 4%

The company said that its revenue fro the One-India business (operations within India) grew 6 per cent year-on-year, crossing ₹3,000 crore for the first time in any opening quarter of a financial year

Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025

Cipla buys 20% stake in iCaltech to broaden respiratory device portfolio

Cipla has acquired a 20% stake in iCaltech Innovations for Rs 5 crore, expanding its presence in the respiratory diagnostics segment with a strategic investment in medical device development

Cipla to enter weight management segment in India: MD & Global CEO Vohra

Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said. The Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche indications...obesity is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra stated. Several domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. US drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug ...

Dividend stocks: HDFC Bank, 18 others to go ex-date on June 27; full list

Among the said list of companies, automaker Swaraj Engines has declared the highest dividend, announcing a final dividend of ₹104.5 per share for financial year 2024-25 (FY25)

Dividend stocks: HDFC Bank, 18 others to go ex-date on June 27; full list

Among the said list of companies, automaker Swaraj Engines has declared the highest dividend, announcing a final dividend of ₹104.5 per share for financial year 2024-25 (FY25)

Breakout stocks: Nifty Pharma, Biocon, Cipla break over 200-DMA; what next?

The Nifty Pharma index and select shares such as Biocon, Cipla, Zydus Life and Gland Pharma were trading above the respective 200-DMAs after more than 2 months; show technical charts.

These 5 pharma stocks can fall up to 12% as technical charts flag caution

Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.

Cipla shares at ₹1,800 or ₹1,465? Analysts divided on pharma stock post Q4

Cipla share price today: Cipla shares today declined 2.9 per cent intraday to hit a low of ₹1,474.1 per share

Cipla Q4FY25 results: Net profit zooms 30% to ₹1,221 cr, revenue up 9%

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent

US govt order to have nil impact on Indian pharma players, says Cipla

The US government's order to pharma firms to lower the cost of prescription medicines within 30 days will not impact Indian generic drugmakers, Cipla MD and Global CEO Umang Vohra said on Tuesday. He noted that the Executive Order signed by US President Donald Trump on Monday is probably going to impact branded drugs. "What we understand is that this is largely targeted towards branded drugs...As of now, what we understand is that this is a voluntary measure that perhaps the companies will be taking," Vohra stated. He noted that there are aspects of MFN clauses etc and it is not clear as of now how and in which manner the Executive Order will be implemented. "So as of now, from a generic perspective, I think generic (drug) prices in the US are already significantly comparable with the rest of the world, in some cases it is lower. So we don't believe that at least for now, based on what the promulgation says we think this is more (towards) branded sector...rather anything on the ...

Cipla Q4 result: Profit rises 30% to ₹1,222 cr; special dividend declared

Cipla Q4 FY25 result: Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share